Results 111 to 120 of about 310,362 (291)

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [PDF]

, 2004
Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by ...
Ahmad, M, Ali, SA, Rees, RC
core   +1 more source

Re-centauring T cell antigen discovery around CD4+ T cells

Cell Reports Methods
In a recent issue of Cell, Dezfulian et al. develop a genome-scale platform to enable high-throughput identification of CD4+ T cell epitopes. This platform enables unbiased screens to discover antigens recognized by CD4+ T cells in cancer, infectious diseases, and autoimmunity.
Smith, Blake E., Chan, Amanda O., Birnbaum, Michael E.   +2 more
openaire   +2 more sources

Advances in Bioprinting to Model Immune‐Mediated Skin Diseases

Advanced Healthcare Materials, EarlyView.
This review explores how 3D bioprinting drives innovation in developing in vitro skin models that mimic immune‐mediated diseases. It highlights current technologies, key applications in studying skin pathologies, and emerging challenges. The review points toward future opportunities for improving disease modeling and advancing therapeutic and cosmetic ...
Andrea Ulloa‐Fernández, Marica Markovic, Julia Fernández‐Pérez, Georg Stary, Aleksandr Ovsianikov   +4 more
wiley   +1 more source

Escherichia coli shares T- and B-lymphocyte epitopes with Schistosoma mansoni

Journal of Infection in Developing Countries, 2009
Background: In this study, we tested the cross-reaction between crude Escherichia coli antigen (ECA) and 3 crude Schistosoma mansoni antigens. Methodology: The schistosomal antigens used were cercarial antigen preparation (CAP), soluble worm antigen ...
Mahmoud Mohamed Bahgat, Hanaa Mohamed Gaber, Amany Sayed Maghraby   +2 more
doaj   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Cytokine Production but Lack of Proliferation in Peripheral Blood Mononuclear Cells from Chronic Chagas' Disease Cardiomyopathy Patients in Response to T. cruzi Ribosomal P Proteins [PDF]

, 2014
Background:Trypanosoma cruzi ribosomal P proteins, P2β and P0, induce high levels of antibodies in patients with chronic Chagas' disease Cardiomyopathy (CCC).
A Moncayo, A Rassi Jr, AC Arnholdt, Alcinette Buying, ARL Teixeira, AS de Melo, Augusto Atienza, B Zingales, C Aznar, C Chen, C Junqueira, C Smulski, Carlos A. Buscaglia, Clemencia Pinilla, CR De Marchi, E Cunha-Neto, E Mahler, E Mahler, E Olivares Fontt, E Olivares Fontt, E Roffê, EA Mesri, EB Gomez, F Kierszenbaum, F Nagajyothi, GE Cánepa, Graciela Perez Prados, GV Levy, I Ferrari, J Scharfstein, J Zhu, JA Fiuza, JAS Gomes, JC Coura, JM Burgos, JM Di Noia, JR Coura, K Elkon, Karina A. Gómez, KM Bonney, Laura M. Tasso, LC Abel, M Juri Ayub, M Ribeirao, MA Zacks, Mauricio Martins Rodrigues, MB Rosenbaum, MJ Morato, MV Elizari, NA Giraldo, P Lopez Bergami, P Lopez-Bergami, PA Chiale, Pablo Chiale, Radleigh Santos, RCG Fares, Ricardo Bonato, S Brandariz, S de Barros-Mazon, S Muller, Silvia A. Longhi, SL Topalian, V Judkowski, V Michailowsky, V Schultena, Valeria A. Judkowski, Virginia Balouz, VMB Lorena, WO Dutra, WO Dutra, WO Dutra, WO Dutra, WR Cuna, Y Belkaid, Y Morán-Utrera, Y Shi   +75 more
core   +4 more sources

Tunable Enhancement of T Cell Expansion Through Modulation of Stiffness and Adhesion Receptor Engagement in an Engineered Hydrogel Platform

Advanced Materials, EarlyView.
We develop a hydrogel scaffold with controlled substrate stiffness and ligand functionalization for cell culture. Stiff substrates presenting CD3/CD28/CD2 ligands induce 2000‐fold expansion of T cells; this is 68% greater than the clinical standard (Dynabeads) and the first hydrogel capable of large‐scale expansion. Although expanding at a lower yield,
Niroshan Anandasivam, Rabia Ali, Lordean Gustinvil, Matthew J. Rosenwasser, Iain E. Dunlop, Derfogail Delcassian   +5 more
wiley   +1 more source

Studying the effect of chloroquine on sporozoite-induced protection and immune responses in Plasmodium berghei malaria [PDF]

, 2015
BACKGROUND Sporozoite immunization of animals and humans under a chemo-prophylactic cover of chloroquine (CPS-CQ) efficiently induces sterile protection against malaria.
Bijker, Else M, Cockburn, Ian, Nganou-Makamdop, Krystelle, Sauerwein, Robert W, van Gemert, Geert-Jan, Zavala, Fidel   +5 more
core   +2 more sources

Remote‐Controllable Immune‐Priming Spot Formation Via Nanocomplexed Hydrogel‐Assisted Histotripsy: Immunoasis

Advanced Materials, EarlyView.
A novel immunotherapeutic strategy combines injectable, adjuvant‐loaded hydrogels with externally controlled histotripsy to create immune‐priming sites within tumors. This approach generates millimeter‐sized immune‐activated lesions with flexible, patient‐tailored treatment scheduling, enabling precise immune activation through tumor ablation‐mediated ...
Sung Hoon Kim, Wonseok Choi, Yurim Kim, Hyeongmin Kim, Gu Won Jeong, Hyewon Park, Inchan Youn, Yoon Park, Sungmin Han, Young‐Min Kim   +9 more
wiley   +1 more source